Christopher Davis, DO
Family Medicine · Greenville, SCNPI 1174056097
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novo Nordisk at 24.3% of the total.
Across 90 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$345
- AbbVie$297
- Dexcom, Inc.$65
- Exact Sciences$59
- Novartis$56
- Pfizer$53
- plus $544 from 18 others
Across 193 payments — averaging $13,924 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- Merck$664K
- Pfizer$526K
- Abbott$187K
- Amgen$95K
- Regeneron$47K
- plus $56K from 3 others
What the payments were for
- Food & beverage$1,419100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $345 |
| AbbVie | 23 | $297 |
| Dexcom, Inc. | 3 | $65 |
| Exact Sciences | 4 | $59 |
| Novartis | 3 | $56 |
| Pfizer | 4 | $53 |
| Amgen | 3 | $53 |
| AstraZeneca(2 entities) | 3 | $52 |
| Inari Medical, Inc. | 2 | $48 |
| Bayer | 3 | $48 |
| Astellas Pharma US Inc | 2 | $46 |
| Abbott | 2 | $41 |
| Cranial Technologies, Inc | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Tris Pharma Inc | 1 | $24 |
| Recor Medical Inc | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $14 |
| Corium, LLC | 1 | $14 |
| Organon | 1 | $13 |
How this compares
$1,419 in reported general payments places this provider in the 65th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 18 | $16,336 |
| Gabapentin | 30 | $776 |
| Celecoxib | 11 | $679 |
| Rosuvastatin Calcium | 30 | $418 |
| Duloxetine Hcl | 18 | $233 |
| Pantoprazole Sodium | 19 | $217 |
| Losartan Potassium | 26 | $215 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $181 |
| Levothyroxine Sodium | 17 | $180 |
| Metformin Hcl | 32 | $161 |
| Amlodipine Besylate | 25 | $160 |
| Atorvastatin Calcium | 36 | $149 |
| Lisinopril | 42 | $91 |
| Trazodone Hcl | 24 | $66 |
| Hydrochlorothiazide | 24 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $345 | $16,33618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Greenville
- Steve HamberisGreenville$19K
- Richard LelandGreenville$19K
- Saria SaccocioGreenville$17K
- Eric FaileGreenville$15K
- Naveen BethiGreenville$14K
- James BridgemanGreenville$13K
- Angela SellGreenville$13K
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.